{"id":29226,"date":"2015-12-01T12:23:48","date_gmt":"2015-12-01T12:23:48","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=29226"},"modified":"2015-12-01T16:57:24","modified_gmt":"2015-12-01T16:57:24","slug":"potential-for-generic-price-for-12-weeks-sofosbuvir-to-drop-below-than-us-300-and-for-daclatavir-to-us-23","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/29226","title":{"rendered":"Potential for generic prices for 12 weeks sofosbuvir treatment to drop below US $300 and daclatasvir to US $23"},"content":{"rendered":"

\"15th<\/p>\n

Simon Collins, HIV i-Base<\/strong><\/p>\n

The potential for even lower prices for generic formulations of new oral hepatitis C drugs was presented as a poster by Andrew Hill from Liverpool University.<\/strong> [1]<\/p>\n

This study used the falling costs of active pharmaceutical ingredients (API) during 2015 related to production efficiency and greater demand in order to model future potential lower target prices.<\/p>\n

Currently, sofosbuvir costs US $50,000 – 84,000 in high-income countries for 12 weeks treatment compared to less than $1000 for generic versions in low- and middle-income countries (produced under license from Gilead). Daclatasvir costs approximately US$ 35,000 for 12 weeks, but information on generic access and prices have not yet been announced by Bristol Myers-Squibb.<\/p>\n

The model included a 40% markup for formulation costs, $0.35 per month for packaging, and a 50% profit margin.<\/p>\n

The model predicted that if API price reductions continue at the current rate, then by the end of 2015 target prices would reach US $281 for sofosbuvir and US $23 daclatasvir.<\/p>\n

Comment<\/h3>\n

The potential to dramatically reduce the price of hepatitis C drugs in low- and middle-income countries is essential given that most people with hepatitis C live in these countries.<\/strong><\/p>\n

It is therefore reassuring that prices for generic sofosbuvir have already fallen in line with this model to less than US$ 400.<\/strong> [2]<\/p>\n

This study further highlights the indefensible pricing structure for sofosbuvir and daclatasvir in high-income countries, putting the drugs beyond the reach of health systems to enable universal treatment for people with hepatitis C.<\/strong><\/p>\n

It is perfectly legal in many countries, including the UK, to use an online pharmacy to important 12 weeks of generic medication for personal use.<\/strong><\/p>\n

The Australian HIV medical association (ASHM) has published online guidance for how to do this, that could be used by people in the UK.<\/strong> [3]<\/p>\n

Prices for other new hepatitis C drugs were included in an earlier presentation by this group at the IAS 2013 conference two years ago.<\/strong> [4]<\/p>\n

References:<\/p>\n

    \n
  1. Hill A et al. Significant reductions in costs of generic production of sofosbuvir and daclatasvir for hepatitis C treatment in low- and middle income countries. 15th EACS, 21-24 October 2015, Barcelona. Poster PE 13\/43.<\/li>\n
  2. hepcasia.com. Updated list of generic manufacturers of sofosbuvir in India plus prices. (10 September 2015).
    \nhttp:\/\/hepcasia.com\/2015\/09\/11\/availability-and-pricing-of-generic-sofosbuvir-in-india-updated-10-september-2015<\/a><\/li>\n
  3. 3.Australian Medical Society issues guidelines for personal importation of generic oral hepatitis C drugs including sofosbuvir. HTB September\/October 2015.
    \n    https:\/\/i-base.info\/htb\/29036<\/a><\/li>\n
  4. 4.Collins S. Pipeline oral HCV drugs and generic global access to DAAs: the need to mirror ARV programmes. HTB July\/August 2013.
    \n    https:\/\/i-base.info\/htb\/21803<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Simon Collins, HIV i-Base The potential for even lower prices for generic formulations of new oral hepatitis C drugs was presented as a poster by Andrew Hill from Liverpool University. [1] This study used the falling costs of active pharmaceutical …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,38,24],"tags":[213],"class_list":["post-29226","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-treatment-access","category-hepatitis-coinfection","tag-eacs-15-barcelona-2015"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/29226","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=29226"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/29226\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=29226"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=29226"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=29226"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}